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Six passages of the mosquito-borne flavivirus yellow fever (YF) wild-type strain Asibi in HeLa cells attenuated the virus for
monkeys and newborn mice and resulted in loss of mosquito competence. Attenuation after the passage in HeLa cells was
not unique to YF virus strain Asibi as demonstrated by the HeLa passage attenuation of wild-type YF virus strain French
viscerotropic virus and YF vaccine virus 17D-204 for newborn mice. In contrast, wild-type strain Dakar 1279 and the French
neurotropic vaccine virus remained virulent for newborn mice after six passages in HeLa cells. Thus not all strains of YF virus
can be attenuated by passage in HeLa cells. Attenuation of YF virus strains Asibi and French viscerotropic virus was
accompanied by alterations in the antigenic and biological properties of the viruses, including changes to envelope protein
epitopes. Attenuation for newborn mice was coincidental with the acquisition by the HeLa-passaged viruses of the
vaccine-specific envelope protein epitope recognized by monoclonal antibody H5. This suggests that this conformational
change may play a role in the attenuation process. Wild-type Dakar 1279, which remained virulent for newborn mice after
passage in HeLa cells, retained its wild-type antigenic character. The genome of Asibi HeLa p6 virus differed from wild-type
Asibi virus by 29 nucleotides that encoded 10 amino acid substitutions: 5 in the envelope protein, 1 in NS2A, 3 in NS4B, and
1 in NS5. The substitution at NS4B-95 is seen in three different attenuation processes of wild-type YF virus, leading us to
speculate that it is involved in the attenuation of virulence of wild-type strain Asibi.Key Words: yellow fever virus; attenuation; flavivirus.
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aINTRODUCTION
The genus Flavivirus of the family Flaviviridae consists
f approximately 68 members, including the prototype
pecies yellow fever (YF) virus (Westaway et al., 1985;
alisher et al., 1989). The genome of YF virus is a single-
tranded, positive-sense RNA molecule that is 10862
ucleotides in length and encodes the structural proteins
core, membrane (M) and envelope (E)] in the 59 quarter
f the genome and eight nonstructural proteins (NS1–
S5) in the remainder of the coding region (Rice et al.,
985). Mosquito-borne YF virus is responsible for the
isease YF, an important public health problem that has
een controlled by the use of live vaccines. Two live-
ttenuated YF vaccines have been developed that share
he following phenotypic properties: loss of viscerotro-
ism, non-mosquito-competence, and antigenic distinc-
ion from wild-type YF virus. French workers attenuated
1 Present address: Department of Microbiology and Immunology,
niversity of North Carolina at Chapel Hill, Chapel Hill, NC 27514.
2 To whom reprint requests should be addressed at Department of
cathology. Fax: (409) 747-2415. E-mail: abarrett@utmb.edu.
309he French viscerotropic virus (FVV) by passage in
ouse brain to generate the French neurotropic vaccine
FNV) (reviewed in Barrett, 1987). This virus was strongly
eurotropic in mice but poorly neurotropic in humans.
eneration of 17D vaccine was achieved by Theiler and
mith (1937) after the passage of wild-type YF virus strain
sibi 176 times in chick embryo tissue. The 17D vaccines
ary in the number of passages from the parent Asibi
irus: 17D-204 substrains between passages 233–243
nd 17DD substrains between passages 286–289 from
sibi. A study of the changes in the genome between
ild-type Asibi virus and its vaccine derivative 17D-204
243 passages from the parent) revealed 67 nucleotide
nd 31 amino acid changes, which represents a diver-
ence in the two sequences of 0.62% at the nucleotide
evel and 0.91% at the amino acid level (Rice et al., 1985;
ahn et al., 1987). A relatively large number of amino
cid changes were found to occur in the E protein, and
he authors concluded that such changes could be re-
ponsible for the reduced viscerotropism displayed by
he vaccine virus. Comparison of the genomes of FVV
nd FNV revealed 77 nucleotide and 36 amino acid
hanges (Wang et al., 1995). Although it is not known
0042-6822/99
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310 DUNSTER ET AL.hich of the changes are responsible for the attenuation
f YF virus, the independent attenuation processes of
sibi and FVV resulted in two identical substitutions in
he respective attenuated derivatives, namely amino acid
6 in the membrane protein (M-36) and NS4B-95 (Wang
t al., 1995). Therefore, a model system for the analysis of
ariants of YF virus obtained after very few passages in
ell culture would contribute to the elucidation of atten-
ating mutations in the genome.
In 1963, it was demonstrated that after only six se-
uential HeLa cell passages of the wild-type YF virus
train Asibi, the virus had lost its ability to cause viscer-
tropic disease in monkeys (Hardy, 1963). In contrast, the
7D vaccine virus was first shown to have a lowered
iscerotropism after 176 passages in whole and minced
hick embryo tissue (Theiler and Smith, 1937). The orig-
nal work (Hardy, 1963) was later confirmed and ex-
ended (Hearn et al., 1965, 1966; Converse et al., 1971).
ore recently, Barrett et al. (1990a) passaged wild-type
sibi virus six times in HeLa cells and demonstrated that
he virus (Asibi HeLa p6) was attenuated for both mon-
eys and newborn mice. Furthermore, using monoclonal
ntibodies (MAbs), it was shown that the Asibi HeLa p6
irus was antigenically different from the parent non-
eLa-passaged virus (Asibi HeLa p0).
This report enhances the studies concerning the effect
f six passages in HeLa cells on different wild-type YF
iruses of varying virulence. It was found that attenuation
f virus for newborn mice occurred rapidly after passage
n HeLa cells with accompanying phenotypic changes of
he virus. Furthermore, the molecular basis of the atten-
ated phenotype was investigated.
RESULTS
assage of wild-type YF virus through HeLa cells
Wild-type YF virus strains Asibi-LP-CDC, FVV, and
akar 1279 were passaged six times in HeLa cells at a
ultiplicity of infection (m.o.i.) of 1–5 with virus being
arvested on or before day 3 postinfection (p.i.) depend-
ng on the degree of cytopathic effect (CPE). Passage of
F Asibi-LP-CDC and FVV viruses did not yield signifi-
ant CPE during the first few passages (HeLa passages
–2 for Asibi-LP-CDC and passages 1–3 for FVV) (Table
). In comparison, YF virus strain Dakar 1279 gave CPE
n less than 3 days throughout all six passages in HeLa
ells. For all three wild-type YF virus strains, CPE was
apid after HeLa passage 4 (p4). The infectivity titers,
etermined by plaque assay in LLC-MK2 cells, revealed
gradual reduction in virus titers until HeLa p5, in which
ignificant amounts of infectivity were present (Table 1).
he exception was YF Dakar 1279 virus, which main-
ained high levels of infectivity throughout the passage
ange (Table 1). There was no significant difference in
nfectivity titer when virus was titrated in HeLa or LLC-K2 cell-based plaque assays (data not shown). Pas- iage of virus in HeLa cells altered plaque morphology.
arental Asibi-LP-CDC virus was uniformally large
laque in size and remained so after four passages in
eLa cells. However, at HeLa p5, there was an alteration
n both plaque size and the time required for their ap-
earance on plaque assays. Asibi-LP HeLa p5 and p6
iruses produced plaques in excess of 0.5 cm at 24 h in
omparison with the 0.3 cm value for non-HeLa-pas-
aged virus after 6–8 days in LLC-MK2 cell monolayers.
similar scenario was observed for FVV and Dakar 1279
iruses where non-HeLa-passaged virus produces small
laques (0.1–0.2 cm) after approximately 5–9 days p.i.
epending on the isolate. After passage in HeLa cells,
apid appearance of large plaques (0.5 cm) within 24 h
.i. in LLC-MK2 cells was observed. The large plaque
orphology coincided with enhanced virus infectivity
iters (Table 1).
assage of vaccine strains of YF virus
hrough HeLa cells
Two YF vaccine viruses (17D-204 UK and FNV-IP) were
assaged through HeLa cells as described above for
ild-type strains. Both vaccine strains gave CPE
hroughout passage in HeLa cells. The rapidity with
hich CPE occurred increased as the passage through
eLa cells advanced. By HeLa p6, both vaccine viruses
xhibited traits that identified them as a HeLa cell-mod-
TABLE 1
Characteristics of YF Virus Strains after Passage in HeLa Cells
Virus
HeLa passage
0 1 2 3 4 5 6
sibi-LP-CDC
CPE 1 2 2 1 1 1 1
Plaque size LP LP LP LP LP LP LP
Infectivity 5.2 4.6 4.2 4.2 3.7 7.5 6.8
VV
CPE 1 2 2 2 1 1 1
Plaque size SP SP SP SP LP LP LP
Infectivity 6.0 5.2 5.0 4.4 4.6 7.0 7.0
akar 1279
CPE 1 1 1 1 1 1 1
Plaque size SP SP SP LP LP LP LP
Infectivity 6.0 6.2 6.2 7.0 6.8 8.0 8.1
7D-204 UK
CPE 1 1 1 1 1 1 1
Plaque size LP LP LP LP LP LP LP
Infectivity 7.2 6.4 6.6 7.2 8.3 8.0 8.0
NV-IP
CPE 1 1 1 1 1 1 1
Plaque size LP LP LP LP LP LP LP
Infectivity 5.7 5.0 5.0 5.9 7.0 7.4 7.0
Note. Titers expressed as log10 PFU/ml. SP, small plaque; LP, large
laque.fied virus preparation: increase in plaque size in LLC-
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311ATTENUATION OF YELLOW FEVER VIRUSK2 cells (0.5 cm after 2 days for HeLa-passaged virus
ersus 0.3 cm after 7 days for non-HeLa-passaged virus)
nd rapid CPE (24 h p.i.). Virus infectivity titers were
etermined by LLC-MK2 plaque assays alone and re-
ealed high levels of infectivity (Table 1).
eactivity of HeLa- and non-HeLa-passaged
F viruses with MAbs in indirect
mmunofluorescence tests
Barrett et al. (1990a) showed that passaging of YF
irus strain Asibi-LP-CDC in HeLa cells changed certain
irus epitopes as detected by MAbs in indirect immuno-
luorescence (IIF) tests. A panel of YF E protein-reactive
Abs were tested against HeLa- and non-HeLa-pas-
aged Asibi-LP-CDC, FVV, and Dakar 1279 viruses. The
anel of MAbs used in this study varied in their speci-
icities and included YF wild-type specific (MAbs S17,
18, and S24), YF vaccine (17D-204, 17DD, and FNV
pecific) (MAb H5), YF 17D (17D-204 and 17DD specific)
MAb H6), and flavivirus group (MAb S44) in reactivity (Sil
t al., 1992). YF wild-type specific MAbs S17, S18, and
24 recognized epitopes for all parent viruses, yet after
ix passages in HeLa cells, Asibi-LP-CDC and FVV vi-
uses had lost their reactivity for these MAbs (Table 2).
ll three of the MAbs remained positive in reaction with
T
Reactivity of HeLa and Non-HeLa Passage
Virus and passage
YF wild-type
S17 S18
Asibi-LP-CDC p0 1 1
p1 2 2
p2 2 2
p3 2 2
p6 2 2
p6b 2 2
FVV p0 1 1
p1 2 6
p2 2 6
p3 2 6
p6 2 6
p6b 2 6
Dakar 1279 p0 1 1
p1 1 1
p2 1 1
p3 1 1
p6 1 1
17D-204 2 2
17DD 2 2
FNV 2 2
Note. 1, Positive IIF; 2, negative IIF; 6, equivocal IIF.
a H6 is 17D vaccine specific.
b MAb reactivity of either Asibi-LP or FVV HeLa p6 viruses after pasakar 1279 HeLa p6 virus. The loss of reactivity of MAbs w18 and S24 with Asibi-LP-CDC and FVV HeLa p6 viruses
ut retention of reactivity with Dakar 1279 HeLa p6 virus
n IIF tests was confirmed in plaque reduction neutral-
zation tests (data not shown). Examination of the inter-
ediate HeLa passages of Asibi-LP-CDC and FVV vi-
uses by IIF showed that wild-type-specific MAbs S17,
18, and S24 lost reactivity after a single passage in
eLa cells (Table 2). Partial fluorescence (i.e., only some
f the infected cells contained antigen recognized by the
Ab) was observed for HeLa-passaged FVV virus with
Ab S18, although the extent was much less than that of
he parent non-HeLa-passaged virus. By analyzing each
f the intermediate HeLa-passaged YF viruses, it was
stablished that reactivity with vaccine-specific MAbs H5
nd H6 was gained between HeLa p2 and HeLa p3 for
sibi-LP-CDC virus, whereas for FVV-infected cells, MAb
5 was positive in IIF tests at HeLa p2 (Table 2). MAb H6,
hich is 17D vaccine specific, remained nonreactive
ith HeLa-passaged FVV-infected cells (Table 2). At no
oint during the passage series did Dakar 1279 virus
eact positively by IIF with either of the vaccine-specific
Abs (Table 2). Interestingly, the antigenic phenotypes
f the attenuated Asibi-LP-HeLa p6 and FVV HeLa p6
iruses remained stable after three sequential passages
n either SW13, Vero, or LLC-MK2 cells (Table 2). IIF tests
iruses with a Panel of MAbs in IIF Tests
MAb
ic YF vaccine specific Flavivirus gp.
S24 H5 H6a S44
1 2 2 1
2 2 2 1
2 2 2 1
2 1 1 1
2 1 1 1
2 1 1 1
1 2 2 1
2 2 2 1
2 1 2 1
2 1 2 1
2 1 2 1
2 1 2 1
1 2 2 1
1 2 2 1
1 2 2 1
1 2 2 1
1 2 2 1
2 1 1 1
2 1 1 1
2 1 2 1
either SW13, LLC-MK2, or Vero cells.ABLE 2
d YF V
specifere also performed with YF vaccine viruses for refer-
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312 DUNSTER ET AL.nce and comparative purposes. YF 17D-204, 17DD, and
NV vaccine virus-infected cells lacked the YF wild-type
pitopes recognized by MAbs S17, S18, and S24. MAb H5
eacted with all (17D-204, 17DD, and FNV) vaccine virus-
nfected cells, whereas MAb H6 reacted with both 17D
ubstrain (17D-204 and 17DD) virus-infected cells but did
ot recognize an epitope on FNV vaccine virus-infected
ells, consistent with their established specificities (Ta-
le 2). 17D-204 and FNV HeLa p6 viruses gave identical
atterns of reactivity with the MAbs as the non-HeLa-
assaged viruses (data not shown).
irulence of HeLa- and non-HeLa-passaged
F viruses for newborn mice
Newborn mice offered a susceptible animal model in
hich to assay the virulence of both HeLa- and non-HeLa-
assaged YF viruses. Mice were inoculated intraperitone-
lly (i.p.) with 100 PFU of virus diluted in PBS. Non-HeLa-
assaged Asibi-LP-CDC, FVV, and Dakar 1279 viruses were
ethal for newborn mice (Table 3). Inoculation of either
sibi-LP-CDC or FVV HeLa p6 viruses i.p. into newborn
ice revealed that the viruses were very attenuated with
nly one death (on day 11 p.i.) being recorded for a mouse
hat had received Asibi-LP-CDC HeLa p6 virus (Table 3). In
omparison, YF Dakar 1279 HeLa p6 virus remained viru-
ent for newborn mice with no animals surviving challenge
Table 3). There were apparent differences between the YF
iruses relating to the point at which attenuation occurred
fter passage in HeLa cells. FVV exhibited attenuated char-
T
Virulence of HeLa- and Non-HeLa-
Virus
He
0 1 2
sibi-LP-CDC
Survivors/inoculated 0/13 0/10 5/14
% Survivors 0 0 36
VV
Survivors/inoculated 0/14 11/12 9/10
% Survivors 0 91 90
akar 1279
Survivors/inoculated 0/10 0/10 0/12
% Survivors 0 0 0
VVpp
Survivors/inoculated 0/13 7/11 NT
% Survivors 100 64 NT
7D-204 UK
Survivors/inoculated 0/12
% Survivors 0
NV-IP
Survivors/inoculated 0/10
% Survivors 0
Note. Mice inoculated i.p. with 100 PFU of virus in 50 ml of PBS. NT
a HeLa p6 viruses after three further passages in SW13 or Vero cellcteristics for newborn mice after a single passage in HeLa iells with only 8% (1 of 11) mortality rate (Table 3). By HeLa
3, FVV was highly attenuated for newborn mice with no
eaths recorded. In comparison, Asibi-LP-CDC virus dis-
layed a gradual decrease in lethality for newborn mice.
sibi-LP HeLa p1 virus was as virulent as the parent virus
ith 100% mortality rate (Table 3). The mortality rate had
ecreased to 64% for newborn mice that were inoculated
ith Asibi-LP p2 virus, but the virus still possessed a high
egree of lethality (Table 3). However, after three passages
n HeLa cells, Asibi-LP-CDC virus was highly attenuated for
ewborn mice (Table 3). Passage of Asibi-LP-HeLa p6 and
VV HeLa p6 viruses in SW13 or Vero cells (three consec-
tive passages) did not greatly alter the virulence pheno-
ype of the attenuated variants, although FVV HeLa p6 1
ero-passaged virus was more virulent than FVV HeLa p6
irus with 79% survivors (Table 3).
All newborn mice that were inoculated i.p. with either
7D-204 UK (derived from Asibi) or FNV-IP (derived from
VV) YF vaccine viruses died with average survival times
ASTs) of 11.2 and 8.5 days, respectively, significantly
xtended in comparison to their wild-type parent viruses.
noculation of 17D-204 UK HeLa p6 virus into newborn
ice resulted in no deaths; however, all newborn mice
noculated with FNV-IP HeLa p6 virus died after inocula-
ion despite extended ASTs (Table 3).
irulence of a plaque-picked FVV HeLa p1 virus
or newborn mice
HeLa cells were inoculated with wild-type FVV and
ed YF Viruses for Newborn Mice
age
p6 1
SW13a
p6 1
Veroa4 5 6
13/14 10/10 9/10 13/13 14/14
93 100 90 100 100
12/13 10/10 10/10 9/9 11/14
93 100 100 100 79
NT 0/10 0/10 NT NT
NT 0 0 NT NT
NT NT 10/10 NT NT
NT NT 100 NT NT
10/10
100
0/10
0
sted.ABLE 3
Passag
La pass
3
11/12
91
13/13
100
NT
NT
NT
NT
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313ATTENUATION OF YELLOW FEVER VIRUSas removed with a Pasteur pipet. Because the
laques were small, the plaque pick was amplified
nce in HeLa cells before the inoculation of newborn
ice. A HeLa TCID50 assay that received extended
ncubation showed a low infectivity titer of 1000
CID50/ml. Mice were inoculated with the plaque
icked FVV HeLa p1 virus, and 70% survived the 21-
ay test period (data not shown).
emperature sensitivity of HeLa- and
on-HeLa-passaged YF viruses
Temperature sensitivity is a phenotypic marker of
ome attenuated viruses. Accordingly, both HeLa- and
on-HeLa-passaged YF viruses were assayed for tem-
erature sensitivity by incubating plaque assays at 31°,
5°, 37°, and 39.5°C. The results showed that both
eLa- and non-HeLa-passaged viruses were non-tem-
erature sensitive with virus replicating at all tempera-
ures examined. Calculation of the efficiency of plating
T
Nucleotide and Deduced Amino Acid Differences be
Nucleotide Asibi
Asibi-LP-CDC
HeLa p6
887 C U
1000 G A
1054 A C
1437 A C
1656 U A
1965a A G
2142 A C
2704a A G
3274a G A
3817a G A
3821b A G
3925a U A
4864a G A
5461 G U
5641a A G
5926b U C
6013a C U
6829a G C
7171a,b A G
7178b G A
7319 G A
9949 U C
10243a G A
10285a U C
10312a A G
10338a C U
10367a U C
10418a U C
10550a U C
a Nucleotide changes shared with strain 17D.
b Nucleotide changes shared with strain FNV.onfirmed the observation (data not shown). Eoss of mosquito-competence of Asibi
eLa-passaged viruses
Important to the attenuation of wild-type YF virus to
evelop the 17D vaccine was the loss of vector compe-
ence (in this case, mosquito competence). YF Asibi-LP-
DC HeLa p5 and p6 viruses were tested for their mos-
uito vector competence as their infectivity titers gave a
ufficient dose for feeding. Both HeLa-passaged YF Asibi
iruses were non-mosquito-competent like the 17D-204
accine virus (data not shown). Thus loss of vector com-
etence took place at or before five passages in HeLa
ells.
ucleotide sequence of the genome of Asibi-LP-CDC
eLa p6 virus
The genome sequence of Asibi-LP-CDC HeLa p6 virus
as determined and found to differ from parental wild-
ype Asibi virus by 29 nucleotides, of which 10 encoded
mino acid substitutions (Table 4). Five of the 10 amino
cid substitutions were found in the E protein (E-27,
Wild-Type Asibi and Asibi-LP-CDC HeLa p6 Viruses
Amino acid Asibi
Asibi-LP-C
CDC HeLa p6
E-27 Q H
E-155 D A
E-228 M K
E-331 K R
E-390 H P
NS2A-48 T A
NS4B-95 I M
NS4B-98 V I
NS4B-144 E K
NS5-900 P LABLE 4
tween-155, E-228, E-331, and E-390): 1 in NS2A, 3 in NS4B
(
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314 DUNSTER ET AL.NS4B-95, NS4B-98, and NS4B-144), and 1 in NS5. Over-
ll, 17 of the 29 nucleotide changes in Asibi-LP-CDC
eLa p6 virus were shared with strain 17D, whereas 4 of
he nucleotide changes were shared with FNV (see Table
). Three of the Asibi-LP-CDC HeLa p6 virus amino acid
ubstitutions were the same as seen in attenuation of
sibi to generate vaccine strain 17D, namely E-331,
S4B-95, and NS5–900. Amino acid NS4B-95 may be
mportant for the attenuated phenotype because an iden-
ical substitution was also seen in attenuation of FVV to
enerate FNV (Wang et al., 1995).
ucleotide sequence of the 59 noncoding region and
tructural protein genes of Asibi-LP-LSHTM HeLa
6 and FVV HeLa p6 viruses
Barrett et al. (1990b) described a large plaque virus of
sibi virus (Asibi-LP-LSHTM) that represents an inde-
endent series of six HeLa passages of strain Asibi for
omparison with Asibi-LP-CDC virus. Over the 2700 nu-
leotides examined at the 59 terminal region of the Asibi-
P-LSHTM HeLa p6 virus genome, a total of only four
ucleotides changes coding for two amino acid substi-
utions were identified. A single nucleotide change was
ound to occur in the M protein gene at nucleotide 948 (U
o C), which corresponded to a V-to-A amino acid sub-
titution at M-67. The E protein gene was found to differ
FIG. 1. Diagrammatic representation of the structure of the ectodom
cid substitutions found in FNV (shaded circles) and FVV HeLa p6 (oprom wild-type Asibi virus by three nucleotides. The nu- gleotide changes at positions 1345 (C to U) and 1948. (A
o U) were noncoding changes. However, the nucleotide
hange at position 1054 (A to C) gave rise to an amino
cid substitution of Q to H (residue E-27). Residue E-27
ay be important in the attenuation process as the same
ubstitution was seen in Asibi-LP-CDC HeLa p6 virus.
FVV HeLa p6 virus differed from wild-type parent FVV
y 5 of the 2700 nucleotides determined, and all the
hanges were in the E protein gene. Changes at nucle-
tides 1819 (C to U) and 2257 (U to C) did not code for
mino acid substitutions, whereas changes at nucleo-
ides 1572 (A to C), 1965 (A to G), and 2193 (C to U) coded
or amino acid substitutions at E-200 (K to T), E-331 (K to
), and E-407 (K to R), respectively. The three amino acid
ubstitutions may be significant because they were all
een in the attenuation of Asibi to generate 17D.
nterpretation of amino acid substitutions
n the E protein
Figure 1 shows a diagrammatic representation of the
hree-dimensional structure of the soluble portion of YF
irus E protein based on the structure of TBE virus
eported by Rey et al. (1995). The amino acid substitu-
ions found in the attenuation of FVV to generate FNV
E-54, E-227, and E-249) and FVV HeLa p6 viruses (E-200
nd E-331) are highlighted. The amino acid substitutions
he flavivirus E protein (modified from Rey et al., 1995) showing amino
les) viruses. (A) Top view. (B) Side view.ain of tenerated by the two attenuation processes do not ap-
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315ATTENUATION OF YELLOW FEVER VIRUSear to be spatially located near to each other, and their
otential role in the attenuation process is unclear. Fig-
re 2 shows the E protein structure with the amino acid
ubstitutions found in the attenuation of Asibi to gener-
te 17D (E-52, E-171, E-173, E-200, E-299, E-305, E-331,
nd E-380) and Asibi HeLa p6 (E-27, E-155, E-228, E-331,
nd E-390) viruses as highlighted. Substitution at E-331
s shared by both attenuation processes. E-27 and E-52
re located spatially near to each other, as are E-155 and
-171, and E-380 and E-390.
DISCUSSION
Between 1963 and 1966, a number of studies were
ndertaken on wild-type YF virus strain Asibi to investi-
ate the attenuation of virus virulence for monkeys after
nly six passages in HeLa cells. It was surprising that so
ew passages in HeLa cells generated a variant virus
hat was highly attenuated for monkeys (700,000 PFU
equired to elicit disease in monkeys) (Hardy, 1963;
earn et al., 1966; Converse et al., 1971). More recently,
ild-type YF strain Asibi was successfully attenuated for
onkeys and newborn mice after six passages in HeLa
ells (Barrett et al., 1990a, 1990b). Furthermore, these
atter studies showed that attenuation of virus virulence
as accompanied by antigenic changes to epitopes
FIG. 2. Diagrammatic representation of the structure of the ectodom
cid substitutions found in 17D (shaded circles) and Asibi-LP-CDC Heresent on the E protein (Barrett et al., 1990a). In addition, Ailler and Adkins (1988) showed that the HeLa p6 virus
ad lost mosquito competence.
In this report, five strains of YF virus were analyzed
nd compared with respect to their biological and ge-
etic characteristics. The strains were chosen to deter-
ine whether attenuation of YF virus on passage in
eLa cells was unique to YF strain Asibi. Due to the
carcity of primates, the newborn mouse was used as a
odel for demonstrating attenuation of virulence. Two
trains of YF virus (Asibi-LP-CDC and FVV) were highly
ttenuated for newborn mice after six passages in HeLa
ells. In comparison, strain Dakar 1279, after a similar set
f passages, remained lethal for newborn mice. Thus not
ll wild-type strains of YF virus can be attenuated after
imited passage in HeLa cells. Analysis of the interme-
iate HeLa passages for their individual virulence char-
cteristics revealed that a significant attenuation of
sibi-LP-CDC virus was apparent by HeLa p3, whereas
he virulence of FVV was highly attenuated after a single
assage in HeLa cells. The attenuation at HeLa p3 for
sibi-LP-CDC coincided with the presence of CPE and
elative stability of the HeLa-passaged virus. However,
his may not be a correlate because this was not ob-
erved for strain FVV. In this respect, Hearn et al. (1966)
ere able to obtain a number of atypical clones of YF
he flavivirus E protein (modified from Rey et al., 1995) showing amino
open circles) viruses. (A) Top view. (B) Side view.ain of tsibi virus after a single passage in HeLa cells. Although
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316 DUNSTER ET AL.he entire population at HeLa p1 was virulent for mon-
eys, clones obtained through plaque purification had an
ttenuated phenotype. This suggests that selection may
ave taken place from the starting population with sub-
equent passages in HeLa cells leading to selective
mplification, genetic modification, and a stable popula-
ion of virus at HeLa p5 and p6. This suggestion is
upported by the plaque pick of wild-type FVV selected in
eLa cells that was attenuated for newborn mice. Exam-
nation of two YF vaccine viruses after passage in HeLa
ells revealed that the 17D-204 virus became attenuated,
hereas the FNV virus did not. The latter result may
eflect the highly adapted mouse neurovirulence of this
irus (Barrett, 1987). This result together with that ob-
ained with the highly monkey virulent Dakar 1279 strain
Monath et al., 1980) suggests that only wild-type YF
trains of moderate or low virulence can be attenuated
y passage in HeLa cells.
The E proteins of the HeLa-passaged viruses were
xamined with MAbs. Although both of the attenuated YF
eLa viruses (Asibi-LP-CDC and FVV) lost reactivity with
ild-type specific MAbs S17, S18, and S24 after a single
eLa cell passage, they were still lethal for newborn
ice. Thus loss of wild-type epitopes does not appear to
orrelate with attenuation of virulence for suckling mice.
n contrast, coincident with the appearance of vaccine
irus epitopes (recognized by MAbs H5 and H6) by IIF at
eLa p3, Asibi-LP-CDC virus became highly attenuated
or newborn mice. However, FVV HeLa p1 virus was
ttenuated for newborn mice, but the vaccine-epitope
ecognized by MAb H5 appeared at p2 and vaccine-
pitope H6, which is 17D specific, did not appear at all.
n contrast, Dakar 1279 remained virulent for newborn
ice and did not acquire the vaccine-epitopes recog-
ized by MAbs H5 or H6. Furthermore, Barrett et al.
1990a) had previously shown that YF strain Asibi lost
eactivity with MAb 117 on passage in HeLa cells and
ained reactivity with vaccine specific MAb 411. In this
tudy, six passages of Asibi-LP virus (used by Barrett et
l., 1990a) in HeLa cells resulted in the reactivity of MAb
17 being maintained while reactivity with MAb 411 was
cquired (data not shown). Hence, despite the retention
f the wild-type epitope, attenuation occurred. Such an-
igenic differences between passage of Asibi virus in
eLa cells and MAb reactivity may be explained by the
act that Barrett et al. (1990a) used the S2 clone of HeLa
ells as opposed to the Normal Clone used throughout
his study. Thus these results suggest that acquisition of
he YF E protein vaccine-epitope recognized by MAb H5
ay be at least coincidental with the attenuation of
ild-type YF virus for newborn mice.
We have previously shown the attenuation of the fla-
ivirus West Nile (WN) strain Sarawak after six passages
n HeLa cells results in a temperature-sensitive virus
ith a 4 log10 reduction in virus infectivity at 39.5°C
Dunster et al., 1990). In contrast, although six passages vf wild-type YF viruses (Asibi-LP and FVV) in HeLa cells
ave rise to highly attenuated variants, these viruses
ere not found to be temperature sensitivity. Because
apanese encephalitis (JE) virus attenuated by passage
n HeLa cells is also non-temperature sensitive (Cao et
l., 1995), it suggests at the very least that the attenuation
f WN HeLa p6 virus is different to that of YF and JE
iruses after passage in HeLa cells.
To help understand the molecular basis of attenuation
f the HeLa-passaged virus, the genome of Asibi-LP-
DC HeLa p6 virus was sequenced; it was found to differ
rom the parental wild-type Asibi virus by 29 nucleotides
ncoding 10 amino acid substitutions. No nucleotide
hanges were found in the 59 noncoding region (59 NCR).
ecause three different attenuation processes (Asibi in
eLa cells, Asibi in chicken tissue to generate 17D, and
VV in mouse brain to generate the FNV) have no nucle-
tide changes in the 59NCR, it indicates that this part of
he genome does not play a role in the attenuation of YF
irus and/or the 59NCR is unable to accommodate mu-
ations and still result in a viable virus (Hahn et al., 1987;
ang et al., 1995). The latter is possible because anal-
sis of the 59NCR of 13 wild-type YF strains revealed that
hey differed at only five positions (Wang et al., 1996). It
as surprising that 17 of the 29 nucleotide changes seen
n Asibi HeLa p6 virus were shared with 17D virus (see
able 4). This may reflect a selective advantage for at-
enuated viruses with a particular genotype or may be
oincidental because only 3 of the 17 nucleotides en-
oded amino acid substitutions.
The E and NS4B proteins encoded the vast majority of
mino acid substitutions (8 of 10). Interpretation of the
mino acid substitutions is difficult because the pheno-
ypic properties of the virus are loss of viscerotropism,
educed mouse neurotropism, and loss of mosquito
ompetence. It is not known whether these phenotypic
haracteristics are controlled by only one, different, or an
ccumulation of genetic changes. However, it is consid-
red significant that all three different attenuation pro-
esses (Asibi through human HeLa cells, Asibi through
hicken tissue, and FVV through mouse brain) exhibit
ttenuation of viscerotropism and loss of mosquito com-
etence and share an identical nucleotide change at
osition 7171 that leads to an amino acid substitution at
S4B-95. However, examination of the NS4B gene of FVV
eLa p6 virus revealed no nucleotide changes from
arental non-HeLa-passaged FVV (data not shown).
hus the amino acid substitution at NS4B-95 may be
ssociated with attenuation of wild-type strain Asibi,
hereas strain FVV is attenuated by different mutations.
he function of NS4B is poorly understood at present, but
t appears to be an integral membrane protein (West-
way et al., 1997). The role of this protein in the attenu-
ted phenotype remains to be elucidated.
The attenuation of two different plaque picks of Asibi
irus (Asibi-LP-CDC and Asibi-LP-LSHTM) by passage in
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317ATTENUATION OF YELLOW FEVER VIRUSeLa cells resulted in an amino acid substitution at E-27,
uggesting that this mutation was not selected randomly
nd may be potentially important in the attenuated phe-
otype of HeLa-passaged Asibi virus. The E protein
odel of Rey et al. (1995) indicates that domain I con-
ains E-27 as well as E-52, E-54, and E-56 found in the
ttenuated vaccines 17D-204, 17DD, and FNV (Barrett,
987; Hahn et al., 1987; Wang et al., 1995). Furthermore,
he proposed folding of this domain suggests that E-27
nd E-52–E-56 may be spatially near to each other (see
ig. 2). If correct, this may explain why the vaccine
pitope shared by all these attenuated viruses. Definitive
nalysis of whether this site is of antigenic and/or patho-
enic importance requires analysis by site-directed mu-
agenesis of an infectious clone of YF virus. Overall, it is
ikely that the few changes observed for the Asibi-LP
eLa p6 virus are closer to true attenuating mutations
ather than the larger number of substitutions in the
ttenuation of Asibi virus to generate 17D, which are
robably cumulative during the 176 passages of Asibi to
enerate 17D. Thus HeLa-passaged attenuated YF virus
rovides a useful model to investigate the molecular
asis of attenuation of YF virus.
MATERIALS AND METHODS
irus strains
Five wild-type isolates of the mosquito-borne YF virus
ere used in the study. These consisted of a large
laque clone of the wild-type virus (Asibi-LP) that was
elected by plaque picking and purifying in Vero cells
Centers for Disease Control and Prevention (CDC), Fort
ollins, CO] and termed Asibi-LP-CDC. This parental
irus was used by Barrett et al. (1990a) in previous
tudies that examined the attenuated phenotype of
eLa-passaged Asibi virus. Similarly, parental Asibi virus
as plaque picked and purified in Vero cells using Asibi
irus obtained from the London School of Hygiene and
ropical Medicine (LSHTM) (Barrett and Gould, 1986).
his virus was termed Asibi-LP-LSHTM and was given
ix passages in HeLa cells (Asibi-LP-LSHTM HeLa p6)
nd has been reported previously (Barrett et al., 1990b).
n addition, the FVV and an isolate from Dakar, Senegal
Dakar 1279) (Wang et al., 1996), were also included. Two
F vaccine viruses, 17D-204 UK (United Kingdom vac-
ine) and FNV-IP, were also included (Wang et al., 1995).
ll viruses were plaque purified after propagation in
uman SW13 cells and twice amplified in mosquito-
erived C6-36 cells. Virus stocks were stored at 270°C
efore passage in HeLa cells.
ells and viruses
Confluent monolayers of HeLa cells (Normal Clone;
low Laboratories, Irving, UK) were grown in Eagle’s
inimal essential medium (EMEM; Flow Laboratories) dontaining 10% newborn calf serum (Flow Laboratories).
eLa cells were seeded into 25-cm2 flasks (Flow Labo-
atories) for the first four passages of virus and passages
and 6 in 80-cm2 flasks (Flow Laboratories). Before
nfection with virus, the confluent HeLa cell monolayers
ere washed with PBS and infected at an m.o.i. of 1–5
FU. After 30-min absorption at room temperature, the
onolayer was washed with PBS to remove unattached
irus and replaced with EMEM containing 1% FCS (Flow
aboratories). Flasks were incubated for up to 3 days or
ntil 80% CPE was evident, whichever came first.
nfectivity titrations
Virus infectivity was determined by plaque assay in
LC-MK2 or HeLa cells. Viral plaques were visualized
fter 3–7 days depending on the virus isolate by staining
ith neutral red (Barrett et al., 1989).
ntigenic analysis using MAbs
Both parent and HeLa-passaged viruses were tested
n plaque reduction neutralization reduction tests in LLC-
K2 cell monolayers as described previously (Barrett et
l., 1989). MAbs were used to study the expression of E
rotein epitopes by IIF. These MAbs were designated
-series (raised against wild-type YF virus strain B4.1)
nd H-series (raised against YF 17DD Brazil vaccine
irus) (Sil et al., 1992). IIF studies were performed as
escribed previously (Barrett et al., 1989).
emperature sensitivity
The infectivity of HeLa- and non-HeLa-passaged vi-
uses was measured by plaque assay as described at
1°, 35°, 37°, and 39.5°C for the requisite number of
ays before visualization of plaques. To confirm temper-
ture sensitivity, the efficiency of plating was calculated.
athogenesis study
Newborn mice 24–48 h old (strain TO; Olac, UK) were
noculated i.p. with 100 PFU of virus diluted in PBS in a
olume of 50 ml. The mice were observed daily for signs
f disease. After observation for 21 days, the AST was
etermined. Results were compared with those for PBS
ock-infected control mice.
osquito competence studies
The strain of Aedes aegypti and the procedures for
nfection and measuring mosquito competence have
een described previously (Jennings et al., 1994).
ucleotide sequencing
Viral RNA was prepared and subjected to RT-PCR
ollowed by sequencing as previously described (Wang
t al., 1995) except that PCR products were sequenced
irectly using an Applied Biosystems 377 automatic se-
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318 DUNSTER ET AL.uencer. Where nucleotide changes from the published
equence of wild-type strain Asibi were identified, RT-
CR and sequencing procedures were repeated to con-
irm the nucleotide change, and the nucleotide found in
arental Asibi virus was compared with that found in the
ublished sequence of Asibi virus (Hahn et al., 1987).
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